Based on successful results of the hormone oxytocin in a rat model of Phelan-McDermid syndrome, oxytocin is moving into clinical trials for people with Phelan-McDermid syndrome. Led by Joseph D. Buxbaum, PhD, Director of the Seaver Autism Center, Seaver researchers revealed this next step at the 2015 International Meeting for Autism Research in Salt Lake City, UT. Click here to learn more.